A 12-week, open-label , all subjects will first receive 2 weeks of placebo drug and then active medication in a dose escalating manner: each patient will first receive 50 mg, after evaluation the option exists to increase the dose to to 100 mg and after another evaluation to 200 mg active study drug, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH)

Registry ID

EUCTR2014-004856-68

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

CymaBay Therapeutics, Inc.

Start date

2015-04-20

Last update

2026-08-16

Conditions

• Homozygous Familial Hypercholesterolemia

Summary

Primary: To evaluate the effect of MBX-8025 on Low Density Lipoprotein Cholesterol (LDL-C).

Locations

• , , France
• , , Netherlands
• , , Norway

Related clinical trials

• The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
• HoFH, the International Clinical Collaborators Registry
• NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia

View on source registry